For Immediate Release

12 June 2018

## **Amarex Leadership Focus: Latest Activities in Industry**

Germantown, MD, USA – Amarex was pleased to have two senior staff speak at two bioscience conferences over the weekend.

Dr. Kazem Kazempour, President & CEO of Amarex, participated in the CEO Roundtable for The 23<sup>rd</sup> Annual Conference of the Chinese Biopharmaceutical Association (CBA), held on Saturday, June 9, 2018 in Gaithersburg, MD. Dr. Kazempour addressed the benefits and challenges in international product development, one of Amarex's major focuses for helping clients achieve maximum efficiency in the product approval process. Amarex utilizes operations in Taiwan and Europe for this purpose.

At the annual meeting of the American Society for Microbiology held June 7-11 in Atlanta, GA, Amarex's Vice President of Clinical Operations, Dr. Kush Dhody, presented primary efficacy results of a pivotal Phase 2b/3 study of PRO 140 for heavily treatment-experienced HIV-1 patients. Earlier this year, Amarex reported that the primary efficacy endpoint was successfully achieved in this study. This poster presentation highlighted these trial results and demonstrated the utility of PRO 140 as a new treatment option for treatment-experienced patients with drug-resistant HIV-1.

## About Amarex Clinical Research

Amarex is a global, full service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs, FDA Applications and Submissions, Applications and Submissions to international Health Authorities, GxP Compliance Audits, Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management and General Consulting. Amarex has taken clients' products through the entire approval process from writing the initial product approval strategy to the marketing approval application with a growing list of approved products. Amarex is committed to cost effective, high quality clinical product development.

Contact:
Patrick J. Burke
Business Development
patrickb@amarexcro.com
20201 Century Blvd., Fourth Floor
Germantown, MD 20874 USA
301.528.7000

www.amarexcro.com